The Technical Analyst
Select Language :
ADiTx Therapeutics, Inc. [ADTX]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

ADiTx Therapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: SELL (auto-tracking)

ADiTx Therapeutics, Inc. is listed at the  Exchange

11.84% $3.40

America/New_York / 28 mar 2024 @ 16:00


ADiTx Therapeutics, Inc.: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 6.67 mill
EPS: -12.00
P/E: -0.280
Earnings Date: May 29, 2024
SharesOutstanding: 1.962 mill
Avg Daily Volume: 0.587 mill
RATING 2024-03-28
B-
Sell
RATINGS
Rating CashFlow: Neutral
Return On Equity: Strong Buy
Return On Asset: Strong Sell
DE: Strong Sell
P/E: Neutral
Price To Book: Strong Sell
QUARTER GROWTHS
2/223/224/221/232/233/23
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -0.280 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.05x
Company: PE -0.280 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 3.09 - 3.71

( +/- 9.24%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2023-11-08 Runge Jeffrey W. Buy 470 Options (right to buy)
2023-11-08 Albanna Rowena Buy 4 702 Options (right to buy)
2023-11-08 Nelson Charles Athle Buy 470 Options (right to buy)
2023-11-08 Albanna Amro A. Buy 9 404 Options (right to buy)
2023-11-08 Pankovcin Corinne Buy 4 702 Options (right to buy)
INSIDER POWER
26.24
Last 84 transactions
Buy: 1 934 500 | Sell: 1 185 103

Forecast: 16:00 - $3.42

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $3.42
Forecast 2: 16:00 - $3.42
Forecast 3: 16:00 - $3.42
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $3.40 (11.84% )
Volume 0.188 mill
Avg. Vol. 0.587 mill
% of Avg. Vol 31.98 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for ADiTx Therapeutics, Inc.

Last 12 Months

Last 12 months chart data with high, low, open and close for ADiTx Therapeutics, Inc.

RSI

Intraday RSI14 chart for ADiTx Therapeutics, Inc.

Last 10 Buy & Sell Signals For ADTX

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Feb 8 - 15:19buy$3.86N/AActive
Profile picture for
            ADiTx Therapeutics, Inc.

ADTX

Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.

Last 10 Buy Signals

Date Signal @
ANTUSDMar 28 - 19:38$9.05
BARUSDMar 28 - 19:383.69
DUSKUSDMar 28 - 19:380.605
BTGUSDMar 28 - 19:36$49.83
STXUSDMar 28 - 19:35$3.44
INJUSDMar 28 - 19:3438.22
EGXUSDMar 28 - 19:30200.44
WBTCUSDMar 28 - 19:3269 625
KP3RUSDMar 28 - 19:3298.54
LEOUSDMar 28 - 19:286.05

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.